πŸ”¬Deep Research

CATX β€” Perspective Therapeutics Inc Β· catalysts, narrative & risks

Β·24 sourcesCATX forecast β†’

Perspective Therapeutics, Inc. (NYSE American: CATX) β€” Research Snapshot

As of the Oct 16, 2026 close, CATX traded around $2.17 (down 7.3% that day), with a market capitalization of roughly $247.7M–$267.1M (sources differ) and a 52-week range of $1.96–$6.16 [8] [11] [14] [20] [26]. It carries a high beta (1.85), negative TTM EPS (-$1.33), ~$236.9M in cash, and no meaningful trailing revenue [8] [20] [24]. It is a clinical-stage radiopharmaceutical developer using its lead-212 (Β²ΒΉΒ²Pb) alpha-therapy platform [3] [24].

Key Recent Catalysts (July–October 2026)


AI-assisted research from the K3vl4r desk β€” not personalized investment advice. More research β†’